Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate…
Nestlé $2.6 billion acquisition of Aimmune Therapeutics
Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with…
American Well strategic partnership with Google Cloud
Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver…
Eli Lilly $1.1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.1…
NN Inc. $825 million sale of life sciences unit to American Securities entities
Davis Polk is advising JP Morgan Securities LLC as financial adviser to NN, Inc. in connection with the $825 million sale of…
Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its…
Personalis $125 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million…
IDEAYA Biosciences $50 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its…